Jun 15, 2026 08:10AM
Jun 15, 2026 08:10AM
May 14, 2026 10:55AM
May 14, 2026 10:55AM
Mar 19, 2026 11:00AM
Oct 17, 2025 08:02AM
Oct 17, 2025 08:00AM Sensei Biotherapeutics Reports New Clinical Results Highlighting Durable Progression Free Survival Data for Solnerstotug in PD-(L)1 Resistant Tumors at the ESMO Congress 2025
Nov 14, 2024 07:30AM
Aug 6, 2024 07:30AM
May 23, 2024 05:11PM
May 23, 2024 05:10PM
May 9, 2024 07:30AM
Feb 28, 2024 07:30AM
Jan 4, 2024 07:30AM Sensei Biotherapeutics Provides Corporate Update and Highlights Key Upcoming Milestones
Aug 3, 2023 07:30AM
May 9, 2023 07:30AM
Apr 20, 2023 07:30AM
Apr 20, 2023 07:30AM
Mar 28, 2023 07:30AM
Mar 21, 2023 07:32AM
Mar 21, 2023 07:30AM Sensei Biotherapeutics Announces Submission of Investigational New Drug (IND) Application for SNS-101, a Conditionally Active VISTA-Blocking Antibody
Feb 6, 2023 07:31AM
Feb 6, 2023 07:30AM
Jan 5, 2023 07:31AM
Jan 5, 2023 07:30AM
Dec 8, 2022 07:31AM
Dec 8, 2022 07:30AM
Nov 21, 2022 07:30AM Sensei Biotherapeutics (SNSE) Collaborates with Washington University, St. Louis for Development of SNS-101
Nov 21, 2022 07:30AM
Nov 10, 2022 09:00AM
Nov 8, 2022 07:30AM
Aug 9, 2022 07:30AM
May 10, 2022 07:30AM
Mar 10, 2022 07:30AM
May 12, 2021 07:41AM Sensei Biotherapeutics Reports First Quarter 2021 Results and Provides Business Update
May 5, 2021 08:05AM
Mar 25, 2021 08:00AM

323,147 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All